Is Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO)’s Fuel Running High? Reports Show Less Sellers

July 13, 2018 - By Robert Reynolds

The stock of Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO) registered a decrease of 5.95% in short interest. TARO’s total short interest was 641,500 shares in July as published by FINRA. Its down 5.95% from 682,100 shares, reported previously. With 46,500 shares average volume, it will take short sellers 14 days to cover their TARO’s short positions. The short interest to Taro Pharmaceutical Industries LTD. Ordinary Share’s float is 6.02%.

The stock increased 0.20% or $0.23 during the last trading session, reaching $116.32. About 10,338 shares traded. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has risen 9.57% since July 13, 2017 and is uptrending. It has underperformed by 3.00% the S&P500.

Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company has market cap of $4.59 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It has a 22.12 P/E ratio. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.

Another recent and important Taro Pharmaceutical Industries Ltd. (NYSE:TARO) news was published by which published an article titled: “Perfect 10 Portfolio Is a Thing of Beauty, Up 43%” on July 10, 2018.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.